Overview

Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Nalmefene is the first drug to obtain Marketing Authorisation in France for reduction of alcohol consumption.
Phase:
Phase 3
Details
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Treatments:
Ethanol
Nalmefene
Naltrexone